Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma


This phase II trial studies how well daratumumab works in treating transplant-eligible participants with multiple myeloma. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread.

SparkCures ID 1052
Trial Phase Phase 2
Enrollment 50 Patients
Trial Sponsors
  • Mayo Clinic
Trial Collaborators
  • National Cancer Institute (NCI)
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Pathologically confirmed diagnosis of multiple myeloma who are transplant eligible and have received any prior induction therapy (with or without maintenance)
  • Measurable MRD in bone marrow within 28 days prior to registration (MPF method)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2 at registration
  • Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support, obtained =< 14 days prior to registration
  • Platelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%, obtained =< 14 days prior to registration
  • Calculated or measured creatinine clearance >= 30 ml/min, obtained =< 14 days prior to registration
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert?s syndrome, in which case the direct bilirubin must be =< 1.5 X ULN, obtained =< 14 days prior to registration
  • Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) =< 3 x ULN, obtained =< 14 days prior to registration
  • Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULN, obtained =< 14 days prior to registration
  • Negative urine or serum pregnancy test for women of childbearing potential
    • NOTE: females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
  • Provide informed written consent
  • Willing to provide bone marrow aspirate and core, and blood samples for correlative research purposes
  • Measurable disease of multiple myeloma at the time of baseline values for disease assessment as defined by at least one of the following:
    • Serum monoclonal protein >= 1.0 g/dL
    • >= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
    • Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio ? Bone marrow plasma cells >= 30%

Exclusion Criteria:

  • Any previous ASCT for multiple myeloma (MM)
  • Any prior therapy with daratumumab
  • Non-secretory MM or known amyloid light-chain (AL) amyloidosis
  • Clinically significant active infection requiring intravenous antibiotics (=< 14 days prior to registration)
  • >= grade 3 neuropathy and/or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS syndrome)
  • Other prior malignancy
    • Exceptions:

      • Adequately treated basal cell or squamous cell skin cancer
      • Any in situ cancer
      • Adequately treated stage I or II cancer from which the patient is currently in complete remission, or
      • Any other cancer from which the patient has been disease free for at least 3 years
  • Concurrent therapy considered investigational

    • NOTE: patients must not be planning to receive any radiation therapy (except localized radiation for palliative care that must be completed prior to starting cycle 1, day 1)
  • Pregnant women
  • Nursing women (lactating females are eligible provided that they agree not to breast feed while taking lenalidomide)
  • Men or women of childbearing potential who are unwilling to employ adequate contraception
  • Major surgery =< 4 weeks prior to registration
  • History of stroke/intracranial hemorrhage =< 6 months prior to registration
  • Clinically significant cardiac illness including New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or >= grade 3 cardiac arrhythmias noted =< 14 days prior to registration
  • Known human immunodeficiency virus positive (HIV+) patients
  • Known hepatitis B or hepatitis C infection
  • Exhibiting clinical signs of meningeal involvement of multiple myeloma
  • Known severe chronic obstructive pulmonary disease or asthma defined as forced expiratory volume (FEV1) in 1 second less than < 60% of expected

US Trial Locations

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Mayo Clinic (Jacksonville)

Jacksonville, FL

Mayo Clinic (Jacksonville)

Jacksonville, FL


There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message